NEW YORK (GenomeWeb News) – BG Medicine has completed a public offering of 6 million shares of its common stock, raising net proceeds of around $12.8 million.
The Waltham, Mass.-based cardiovascular diagnostics firm said that the underwriters of the offering also exercised their option to purchase 900,000 additional shares. The offering, which was priced at $2 per share, was launched last week.
Proceeds from the offering will go toward operations, including advancing commercialization of BGM's tests in the US and Europe, as well as general corporate purposes, the firm said.